Written by :
Posted on :

August 1, 2022

Kolosis BIO Announces the Appointment of Michelle Soleimani-Mafi as Director of Operations

Salt Lake City, Utah, August 1, 2022

Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Michelle Soleimani-Mafi as its Director of Operations.


“Success in our industry is built through responsiveness to our customers. There’s no other way. Michelle from day one provides experienced leadership to our operations group delivering on our promise of Relentless Execution,” said Maxwell Hunter, Chief Operating Officer. “She’s built a reputation over years for her passionate commitment to her customers and I look forward to her impact here at Kolosis.”

Prior to joining Kolosis, Michelle spent 16 years at Orthofix where she ultimately held the position of Regional Manager representing MTF bone graft tissues.

“I’m delighted to be a part of what Kolosis is building and to reunite with a team that I’ve known for years,” said Michelle Soleimani-Mafi. “Our combination of best-in-class technologies from MTF with this team’s commercial prowess is truly exciting and I look forward to being a big part of the success story here at Kolosis!”

About Kolosis BIO:

Kolosis BIO is a leading provider of innovative biologic solutions, dedicated to commercializing cutting-edge technologies and delivering market-leading products to the orthopedic industry. As a pure-play biologics company, Kolosis BIO exclusively partners with MTF Biologics to offer superior quality bone graft technologies such as Kore Fiber, a 100% cortical fiber allograft and Prime HD, a pre-hydrated DBM. These allografts are backed by MTF’s proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.

As the company looks to the future, Kolosis is dedicated to driving innovation in the biologics field, expanding its product offerings and pushing the boundaries of science to enhance patient outcomes. With a focus on relentless execution and bold technologies, Kolosis BIO endeavors to become a leading force in the biologics market. For more information, please visit

About MTF Biologics:

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. They provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients across the globe. For more information, visit